PSB-16671 is a novel orthosteric and allosteric activator of GPR84, activates human GPR84 with EC50 of 41.3 nM in cAMP accumulation assays. PSB-16671 is selective versus related fatty acid receptors and the arylhydrocarbon receptor. PSB-16671 shows an EC50 of 5.47 uM in β-Arrestin assays, and allosteric KB value of 634 nM.

GB111-NH2 (Z-Phe-Lys-AOMK) is a novel cysteine cathepsin inhibitor that blocks the activity of cathepsins B, L and S. GB111-NH2 (Z-Phe-Lys-AOMK) inhibits autophagy and increases oxidative stress, specifically trigger macrophage cell death.

CBD3063 is a selective, first-in-class, CRMP2-based peptidomimetic small molecule, which allosterically regulates Cav2.2 to achieve analgesia and pain relief without negative side effect profiles.

A novel and seletive HDAC6 inhibitor.

Clovibactin is an antibiotic isolated from uncultured soil bacteria. Clovibactin efficiently kills drug-resistant Gram-positive bacterial pathogens without detectable resistance. Clovibactin blocks cell wall synthesis by targeting pyrophosphate of multiple essential peptidoglycan precursors.

SP 600125, negative control (SPM1) is an alkyl derivative of pyrazoloanthrone, which can be used as a negative control for SP600125.

ABBV-318 is a potent Nav1.7/ Nav1.8 blocker, with IC50s of 2.8 μM and 3.8 μM for hNav1.7 and hNav1.8, respectively. ABBV-318 can be used for the research of pain.

LY3522348 is a highly selective, oral dual inhibitor of human ketohexokinase isoforms C and A (hKHK-C, hKHK-A). LY3522348 displayed a robust pharmacodynamic response in a mouse model of fructose metabolism and was advanced into clinical trials.

AM-2-19 (SF001) is an ergosterol-extracting polyene antifungal that is discovered through modifications to the amphotericin B toxin by chemists.

GPS491 (EC50 = 0.47 μM) suppresses expression of the HIV-1 structural protein Gag and alters HIV-1 RNA accumulation, decreasing the abundance of RNAs encoding the structural proteins while increasing levels of viral RNAs encoding the regulatory proteins.

SU-909 (SU909, IKKα-IN-48) is a potent, selective IKKα inhibitor with Ki of 0.08±0.07 uM, 10-20-fold selectivity over IKKβ (IC50=1.0±0.28 uM); inhibits FCS-stimulated phosphorylation of p100 in U2OS cells with IC50 of 8.8 uM, inhibits the noncanonical NF-kB pathway without affecting IKKβ-dependent IKappa-Bα loss in the canonical pathway.

INX-315 is a novel and potent CDK2 inhibitor with IC50 of 2.3 nM and shows high selectivity over other CDK family members (374 nM against CDK1/cyclin and 950 nM against CDK9/cyclin,respectively). INX-315 promotes retinoblastoma protein hypo-phosphorylation and therapy-induced senescence (TIS) in CCNE1-amplified tumors, overcomes breast cancer resistance to CDK4/6i and delays the onset of CDK4/6i resistance in breast cancer.

First reported nonpeptidomimetic agonist on the G protein-coupled chemokine receptor CXCR-3

A peptidic glucagon like peptide 2 (GLP-2) analogue for treatment of type2 diabetes..

MTK458 (MTK-458) is a potent, selective and brain penetrant PINK1 activator, MTK-458 promotes the first step in mitophagy. MTK458 selectively activates PINK1 by stimulating dimerization and stabilization of the PINK1/TOM complex. MTK458 binds to PINK1 and stabilizes an active heterocomplex, thereby increasing mitophagy. MTK458 reduces the PINK1 substrate pS65-Ubiquitin (pUb) in primary neurons and in vivo. MTK458 drives clearance of pathologic α-synuclein in vitro and in vivo, decreases pS129 α-synuclein aggregates and normalized both brain and corresponding plasma pUb levels in both cellular and animal models of α-synuclein aggregation (PD-like pathology).

BMS-986172 is a highly Potent MGAT2 Inhibitor that Achieved Targeted Efficacious Exposures at a L BMS-986172 showed on-target- and mechanism-based pharmacology. Moreover, its favorable pharmacokinetic (PK) profile and the lack of species variability in the glucuronidation potential resulted in a greater confidence level in the projection of a low dose for achieving targeted efficacious exposures in humans. Consistent with these projections.

TAK-994 is an oral, selective OX2R agonist developed by Takeda for the treatment of narcolepsy type 1 (with cataplexy) and type 2 (without cataplexy). The molecule follows Takeda’s previous clinical molecule, TAK-925 (danavorexton), which was the first OX2R agonist to be tested in people with NT1 but had poor oral bioavailability and was administered intravenously in the clinic.

KIO-301 – A photoswitchable HCN channel blocker with positive initial results from a Phase I/II for retinitis pigmentosa and choroideremia study that is being developed by KIORA Therapeutics.

Ebio1 is a selective voltage-gated potassium channel KCNQ2 activator. Ebio1 activates KCNQ2 by generating an extended channel gate with greater conductance at a saturation voltage (+50 mV).

SMD-3040 is a potent and selective SMARCA2 degrader with DC50 of 12 nM and demonstrates an excellent degradation selectivity for SMARCA2 over SMARCA4. SMD-3040 achieves strong tumor growth inhibition in two SMARCA4-deficient xenograft models at well-tolerated dose schedules.

NP3-562 is a potent, orally bioavailable, tricyclic NLRP3 inhibitor with IC50 of 0.26 μM in the FP binding assay. NP3-562 demonstrates excellent potency in human whole blood and full inhibition of IL-1β release in a mouse acute peritonitis model.

mPEG-DMG, MW 5,000 is a large PEG lipid containing a DMG group and a methoxy cap. The methoxy cap is inert while the DMG group is a popular ligand for developing PEG-lipids and lipid nanoparticles more broadly. Varying the size of a PEG linker greatly impacts its molecular dynamics, thereby affecting DMPK and ADME properties of a given API.

CBI1 (covalent BAX inhibitor 1) is a compound that selectively derivatizes BAX at C126 with BME50 value of 905 μM. CBI1 inhibits BAX activation by triggering ligands or point mutagenesis.

LY3130481 (CERC611) is a potent, selective, noncompetitive TARP γ8-associated AMPA receptors with IC50 of 65.3 nM (GluA1/TARP γ-8), with no activity for γ-2 (cerebellum) or other TARP members.

DCAF1-BRD9 PROTAC DBr-1 potently degrades BRD9 with a DC50 of 90 nM but only weakly affected BRD7 protein levels. DBr-1 provides an alternative strategy to tackle intrinsic resistance to VHL-degrader.

CPI-0610 is a small molecule inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, the BET inhibitor CPI-0610 binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth.